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Abstract
Background: Arterial proteoglycans are implicated in the pathogenesis of atherosclerosis by their
ability to trap plasma lipoproteins in the arterial wall and by their influence on cellular migration,
adhesion and proliferation. In addition, data have suggested an anti-atherogenic role for heparan
sulfate proteoglycans and a pro-atherogenic role for dermatan sulfate proteoglycans. Using a non-
human primate model for human diabetes, studies examined diabetes-induced changes in arterial
proteoglycans that may increase susceptibility to atherosclerosis.
Methods: Control (n = 7) and streptozotocin-induced diabetic (n = 8) cynomolgous monkeys
were assessed for hyperglycemia by measurement of plasma glycated hemoglobin (GHb). Thoracic
aortas obtained at necropsy, were extracted with 4 M guanidine HCL and proteoglycans were
measured as hexuronic acid. Atherosclerosis was measured by enzymatic analysis of extracted
tissue cholesterol. Glycosaminoglycan chains of arterial proteoglycans were released with papain,
separated by agarose electrophoresis and analysed by scanning densitometry.
Results: Tissue cholesterol was positively associated with hexuronic acid content in diabetic
arteries (r = .82, p < .025) but not in control arteries. Glycosaminoglycan chain analysis
demonstrated that dermatan sulfate was associated with increased tissue cholesterol in both
control (r = .8, p < 0.05) and diabetic (r = .8, p < .025) arteries, whereas a negative relationship
was observed between heparan sulfate and tissue cholesterol in diabetic arteries only (r = -.7, p <
.05). GHb, which was significantly higher in diabetic animals (8.2 ± 0.9 vs 3.8 ± 0.2%, p < .0005) was
negatively associated with heparan sulfate in diabetic arteries (r = -.7, p < .05).
Conclusions: These data implicate hyperglycemia induced modifications in arterial proteoglycans
that may promote atherosclerosis.
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Background
Cardiovascular disease (CVD) is the major complication
of diabetes, leading to 70–80% of deaths in diabetic indi-
viduals [1-3]. The relative risk of CVD for diabetic versus
non-diabetic individuals is 2–3 for men and 3–4 for
women [4-9]. This risk is independent of established risk
factors such as hypercholesterolemia, hypertension and
cigarette smoking [6], indicating that factors unique to the
diabetic state may be important contributors to macrovas-
cular processes leading to CVD. As such, hyperglycemia
has been postulated to contribute significantly to the
increased risk of CVD associated with diabetes, and epide-
miological studies have shown that in diabetic patients,
the higher the plasma glucose, the higher the incidence of
CVD [10-13]. In a recent study, glycated hemoglobin
(GHb), a marker of blood glucose concentration, was
shown to explain most of the increased mortality risk in
men with diabetes [14].
The mechanism is unknown by which hyperglycemia may
confer increased risk for CVD but may involve processes
operative at the level of the artery wall. Atherosclerosis
involves the deposition and accumulation of lipid from
apolipoprotein B (apoB)-containing lipoproteins in cells
and in the extracellular matrix of large vessels [15,16]. The
process of entrapment and retention of LDL in arterial tis-
sue is proposed to be mediated by arterial proteoglycans
(PG). This is based on studies showing co-isolation of gly-
cosaminoglycans (GAG), the carbohydrate moieties of PG
with lipid from human atherosclerotic lesions [17,18]
and immunogold labeling [19] and ultrastructural studies
[20] showing LDL associated with extracellular matrix PG
in rabbit arteries. In a recent study using transgenic mice
expressing recombinant LDL with site specific mutations
in apoB, animals with PG-binding-defective LDL devel-
oped significantly less atherosclerosis than animals
expressing wild type LDL [21].
It has been understood for many years that all proteogly-
cans are not equally atherogenic, with an atherosclerosis-
promoting role associated primarily with PG bearing der-
matan sulfate (DS) chains [22]. By contrast, an anti-ather-
ogenic role has been proposed for heparan sulfate (HS)
proteoglycans based on their ability to inhibit monocyte
binding to the sub-endothelial matrix [23], to regulate
fibroblast growth factor [24], and to inhibit arterial
smooth muscle cell proliferation [24,25]. Increased risk
for atherosclerosis may therefore be conferred by diabe-
tes-associated biochemical processes that produce modifi-
cations in arterial PG. An earlier report indicated that in
human arteries, an atherosclerosis-associated decrease in
the ratio of HS to DS was further decreased with diabetes
[26]. Our previous studies using a non-human primate
model of streptozotocin-induced diabetes, demonstrated
increased atherosclerosis at all arterial sites in the diabetic
group [27]. The present studies were conducted to deter-
mine whether hyperglycemia in these animals was associ-
ated with changes in arterial PG that may promote the
development of atherosclerosis.
Research design and methods
Animals
The animals used as a source of arteries for these studies
have been previously described [27-29]. Briefly, they were
adult male cynomolgous monkeys (Macaca fascicularis)
that received streptozotocin (Zanosar*, The Upjohn Co.,
Kalamazoo, MI) as an intravenous bolus (30 mg/kg). All
animals were fed a moderately atherogenic diet (0.28 mg
cholesterol/kcal, 45% calories from fat) for 2 months
prior to baseline measurements and throughout the 6
month trial period. Fasting blood glucose measurements
were taken routinely following induction of hyperglyc-
emia and exogenous insulin therapy was initiated. Total
daily insulin doses were 4 to 26 U (1 to 5 U/kg weight
administered intramuscularly twice daily). Control ani-
mals were given saline injections on a similar schedule.
Intravenous glucose tolerance tests performed prior to
and 6 weeks after induction of diabetes, resulted in similar
disappearance of plasma glucose in streptozotocin-treated
animals to that measured in spontaneously diabetic ani-
mals [28]. Other clinical assessments including plasma
insulin, GHb and plasma lipids have been fully described
[27-29]. All procedures involving animals were conducted
in strict accordance with "The Principles of Laboratory
Animal Care" (NIH Publication No. 85-23) and in com-
pliance with state and federal laws, standards of the U.S.
Department of Health and Human Services and guide-
lines established by the Institutional Animal Care and Use
Committee.
Proteoglycan preparation
At necropsy the arteries were excised, stripped of adventi-
tia, and quick-frozen in liquid nitrogen for storage at -
70°C. For PG extraction, tissues were thawed, weighed,
minced into 2–3 mm2 pieces, and incubated for 48 hours
at 4°C in 4.0 M Guanidine HCL, 0.05 M sodium acetate
(pH 4.5, 3 ml/mg wet tissue) containing protease inhibi-
tors (0.1 M 6-aminohexanoic acid, 10 mM disodium
EDTA, 5 mM benzamidine hydrochloride, 3 mM phenan-
throline, 5 mM tryptamine HCL). Following extraction,
fluids were removed, tissues were rinsed with 1 ml guani-
dine HCL and rinses and extracts were combined. PG
remaining in tissues were termed extraction-resistant PG.
Based on measurement of purified GAG, similar levels of
extractable PG were present in control (70 ± 5% of total
PG) and diabetic tissues (74 ± 3% of total PG, mean ±
SEM).Cardiovascular Diabetology 2004, 3 http://www.cardiab.com/content/3/1/6
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Purification of GAG
From guanidine-extracted PG
Extracts were dialysed into versene buffer (0.1 M sodium
acetate:0.05 M cysteine HCl; 0.01 M disodium EDTA;
7:1:1 v/v/v) pH 6.0, and GAG were released by digestion
with 10 µg papain, 5 hours, 65°C, repeating addition of
papain after 1 hour. Following papain release, GAG were
complexed to a final concentration of 1% with cetylpyrid-
inium chloride (CPC), 24 hours, 26°C, and separated by
centrifugation at 1400 × g for 30 minutes. Complexes
were dissociated by addition of 2MNaCl: absolute ethanol
(100:15, v/v) and GAG were precipitated by addition of 2
volumes absolute ethanol. After incubation for 24 hours
at 26°C, GAG were separated by centrifugation at 1400 ×
g for 30 minutes and pellets were air-dried. Recoveries at
all stages of purification were monitored by dimethylene
blue assay [30] of discarded fractions. No GAG were
detected in these fractions.
From guanidine-extracted tissues. (extraction-resistant 
PG)
Dried delipidated tissues were rehydrated by incubation
for 2 hours in versene buffer followed by addition of 10
ug papain/mg dry tissue. GAG liberation and purification
was conducted as described for guanidine-extracted PG
with the exception of an additional purification step as
follows to remove contaminating DNA in the tissue
extracts: GAG-ethanol precipitates were solublized in 500
µl of dH2O, adjusted to a final concentration of 10%
trichloroacetic acid, 0.01% BSA and incubated on ice for
1 hour. Precipitated DNA was removed by centrifugation
at 1400 × g, 30 minutes and the supernatant containing
GAG was dialysed vs dH2O and dried by speed-vac. GAG
pellets were dissolved in dH2O and hexuronic acid con-
tent was measured by the method of Blumenkrantz and
Asboe-Hansen [31].
Identification of GAG
GAG were separated by agarose electrophoresis (150
volts, 2 hour, 10°C) using 0.5% agarose gels and a buffer
of 0.05 M 1,3, diaminopropane pH to 9.0 with acetic acid
[32]. Gels were fixed with 0.1% hexadecyltrimethylam-
monium bromide for 3 hours, air-dried I hour, stained
with 0.1% toluidine blue, 0.1% alcian blue in acetic
acid:ethanol:water (0.1:5:5) for 30 minutes and destained
for 30 minutes. GAG were identified by comparing their
migration with those of authentic commercial GAG.
Staining of the individual GAG was linear over the range
used (2–10 ug) and all samples were loaded within this
range. Stained gels were air-dried overnight, scanned
using a UMAX Astra 1220S, and scans were analysed using
Scion Image software from Scion Corporation, Frederick,
MD. Amounts of individual GAG were calculated based
on areas under the curves as a percentage of total GAG
loaded. Total GAG were calculated as the sum of GAG
from guanidine-extractable and extraction resistant PG.
Measurement of tissue cholesterol
Lipid extraction for measurement of cholesterol was per-
formed with tissues following guanidine HCL extraction
to remove extracellular matrix PG and before papain
digestion to isolate GAG from membrane associated PG.
After guanidine extraction, tissues were rinsed with dis-
tilled water, air-dried, and delipidated by extraction with
1:1 (v/v) absolute ethanol:acetone (10 volumes × tissue
weight) at 50°C for 1 hour. Extracts were removed and
extractions were repeated with additional ethanol:acetone
overnight at 26°C and then with acetone alone for I hour
at 26°C. A pool of extracts for each sample was evapo-
rated to dryness, resolublized in 1 ml chloroform, 0.5%
Triton X-100 and again evaporated to dryness [33]. The
dried extracts were dissolved in 0.5 ml of 0.15 M NaCl and
assayed for total cholesterol using an enzymatic assay rea-
gent (Cat. No. 23669, Boehringer Mannheim Diagnostics,
Indianapolis, IN, USA). No GAG were detected in the
extract by dimethylene blue assay.
Immunostaining
Slides prepared from paraffin sections of grossly normal
thoracic aortas were deparaffinized, hydrated, blocked
with 1% BSA in phosphate buffered saline and incubated
overnight at 4°C with a 1:1000 dilution of primary anti-
body to HS GAG chains (HepSS-1, Seikagaku America,
Inc., Ijamsville, MD). A horseradish peroxidase system
was used for detection and cells were stained with
hematoxylin.
Data analysis
Values are presented as mean ± SEM. Statistically signifi-
cant differences were determined by Student's t-test. P val-
ues less than 0.05 were considered significant.
Relationship between variables was determined by linear
regression analysis.
Results
Group measures comparing control and diabetic mon-
keys at time of necropsy are shown in table 1. GHb was
the only parameter measured that was significantly higher
in the plasma of diabetic animals compared to control.
Mean total plasma cholesterol was 30% higher for the dia-
betic group but this did not reach statistical significance.
Likewise, slightly higher tissue cholesterol measurements
in both the thoracic aortas (TA) and carotid artery (CA)
segments from diabetic animals were not significantly dif-
ferent from control. A strong positive relationship was
observed between TA cholesterol and CA cholesterol (r =
0.86, p < 0.0005 for both groups combined). In the same
artery segments used to measure cholesterol, total GAG,
expressed as hexuronic acid (UA) was also similarCardiovascular Diabetology 2004, 3 http://www.cardiab.com/content/3/1/6
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between control and diabetic groups for both TA and CA
(table 1).
Further analyses were conducted to determine the rela-
tionship of GAG with tissue cholesterol accumulation in
the TA segments. As shown in figure 1, whereas total GAG
and cholesterol were not related in tissues from control
animals (figure 1A), in tissues from diabetic animals,
there was a positive correlation between arterial GAG and
cholesterol concentrations (figure 1B). Individual GAG
were separated by agarose electrophoresis and gels were
stained with a combination of alcian and toluidine blue
and then scanned by densitometry. Commercials stand-
ards were used to identify the migration positions of the
GAG: dermatan sulfate (DS), chondroitin sulfate (CS),
and heparan sulfate (HS). Figure 2 shows the staining pat-
terns and densitometric scans of representative standards
and samples. The double staining technique resulted in
similar staining efficiencies in standards of 2 to 6 µg (lanes
1–3) that were linear up to 10 µg (not shown). Lanes 4–6
show staining patterns and scans of 3 different samples:
Lanes 5 and 6 are representative samples of papain-liber-
ated GAG of PG isolated from the tissues by extraction
with 4 M guanidine hydrochloride. All three of the major
sulfated arterial GAG were identified in these samples. For
CS and HS, the migration positions of standards and sam-
ples were similar, but for DS the slight difference in migra-
tion suggested composition or structural differences in the
arterial DS compared to the standard. Lane 4 shows GAG
of extraction-resistant PG. No DS was identified in these
samples.
Determinations of arterial content of specific GAG were
made based on areas under densitometric peaks and con-
version to hexuronic acid per mg delipidated tissue (dlt).
No group differences were observed between control and
diabetic arteries in amounts of any specific GAG (Table 2).
Based on hexuronic acid, control arterial tissue contained:
1.8 ± 0.3 µg CS, 0.7 ± 0.2 µg DS and 0.9 ± 0.1 µg HS/mg
dlt and diabetic arteries contained: 2.1 ± 0.6 µg CS, 0.8 ±
0.3 µg DS and 1.1 ± 0.2 µg HS/mg dlt. Correlation analy-
ses were performed to identify any relationships that may
be associated with tissue cholesterol and specific for the
diabetic state. As a percent of total GAG, only DS was pos-
itively related to increased tissue cholesterol in both con-
trol (r = 0.8, p < 0.05) and diabetic (r = 0.8, p < 0.025)
arteries (figure 3). A negative association was observed
between HS and tissue cholesterol in diabetic arteries only
(r = 0.7, p < 0.05, figure 3B). GHb, which was significantly
higher in the plasma of diabetic animals (table 1), was
negatively associated with HS in diabetic arteries (figure
4). No associations were observed between arterial CS or
DS and GHb. Moreover, no associations were observed
between total plasma cholesterol, HDL-C or LDL-C and
arterial GAG from either control or diabetic animals (data
not shown).
To determine the distribution of HS in the TA of these ani-
mals, sections of histologically normal aortic tissue were
immunostained with an anti-HS GAG antibody. As
shown in Figure 5, distribution of immunoreactive prod-
uct was primarily sub-endothelial with minimal distribu-
tion observed in the media. This is consistent with a major
role for endothelial cells in the production of arterial HS.
Discussion
The goal of these studies was to identify diabetes-induced
changes in arterial PG which may enhance the susceptibil-
ity of the artery to atherosclerosis or lesion progression.
We have previously shown that in these animals, all arte-
rial sites of the diabetic group had more tissue cholesterol
than the control group [27]. Moreover, consistent with the
increased arterial cholesterol content, the diabetic animals
had significantly greater intimal area in both femoral
arteries and abdominal aortas. In these animals also,
altered measures of glucose tolerance, and increased gly-
cation of hemoglobin and skin have confirmed a state of
chronic hyperglycemia in the diabetic group [28]. In the
present study, the segments of thoracic aortas used did not
show group differences in cholesterol content. However
with a range of atherosclerosis in both groups and a range
of GHb values in the diabetic group, it was possible to
detect associations between GAG and the glycemic state of
the animal and also with early cholesterol accumulation
in the arteries. These data support the hypothesis that
hyperglycemia induces alterations in arterial PG.
Table 1: Group differences between control and diabetic monkeys
TPC mg/dl GHb % TA Chol mg/g dlt CA Chol mg/g dlt TA UA mg/g dlt CA UA mg/g dlt
C (7) 343 ± 47 3.8 ± 0.3 31.6 ± 11.3 42.4 ± 14.1 3.4 ± 0.4 7.4 ± 0.6
D (8) 456 ± 43 8.2 ± 0.8* 40.6 ± 12.6 54.1 ± 19.6 4.1 ± 0.9 8.7 ± 0.9
* p < 0.0005 Values are means ± SEM for Control (C, n = 7) and Diabetic (D, n = 8) animals. TPC, Total Plasma Cholesterol; GHb, glycated 
hemoglobin; TA, thoracic aorta; CA, carotid artery; Chol, tissue cholesterol; UA, hexuronic acid; dlt, delipidated tissueCardiovascular Diabetology 2004, 3 http://www.cardiab.com/content/3/1/6
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A positive relationship was observed between total GAG
and cholesterol accumulation in diabetic but not control
arteries. In human arteries, the content of sulfated GAG
has been shown to increase in early lesions but decrease
with lesion development [34,35]. More importantly
atherosclerosis-associated changes in specific GAG have
been reported. The most consistent findings are an
increase in DS and CS and a decrease in HS [36,37]. In
rhesus monkeys, total GAG and DS were positively related
to aortic cholesterol but, as in control animals in the
present study, no relationship was found between arterial
HS and tissue cholesterol [38].
Wasty et al. [26] have previously compared the GAG con-
tent of normal artery and atherosclerotic lesions from
both non-diabetic and Type 2 diabetic individuals. That
study was conducted with autopsy specimens, from aged
individuals (57–92 years) having a wide range in duration
of diabetes (3->15 years) and with significant atheroscle-
rosis. In tissues from non-diabetic subjects, total GAG was
lower in plaque compared to normal intima. The most
significant change observed was a decrease in the ratio of
HS:DS with atherosclerosis in both non-diabetic and dia-
betic tissues. Comparison of the diabetic and non-diabetic
groups showed no difference in total GAG but a signifi-
cant change in distribution: an increase in DS and a
decrease in HS in the diabetic tissues. These data indicated
that atherosclerosis-associated changes in GAG were exac-
erbated in the diabetic state. The findings of the present
study using a non-human primate model of chemically-
induced diabetes extend those of Wasty et al [26] by exam-
ining GAG changes in relation to the glycemic state of the
animals. In the present study, the increase in DS was asso-
ciated with tissue cholesterol content in both groups of
animals whereas the negative association in diabetic ani-
mals between arterial HS content and plasma GHb sug-
gest that the reduction in HS may be an early event in the
pathologic consequences of hyperglycemia.
The idea that some GAG may exert pro-atherogenic and
some anti-atherogenic effects has been reinforced by a
number of observations. A pro-atherogenic role for DS is
supported by studies demonstrating a high affinity of DS
for plasma LDL [39] and by the preferential localization of
biglycan, a DS-containing proteoglycan, to lesion tissue
[22]. Thus DS is proposed to be major factor in retention
Relationship between GAG and tissue cholesterol in segments of thoracic aorta from control and diabetic monkeys Figure 1
Relationship between GAG and tissue cholesterol in segments of thoracic aorta from control and diabetic monkeys. Tissues 
were collected at necropsy, 6 months after induction of diabetes mellitus. GAG values are total hexuronic acid / mg delipidated 
tissue. The correlation coefficient and significance is given. Y = 7.33X + 0.78.
048 1 2
mg GAG/g dlt
0
40
80
120
m
g
 
c
h
o
l
e
s
t
e
r
o
l
/
g
 
d
l
t
Control
048 1 2
mg GAG/g dlt
0
40
80
120
m
g
 
c
h
o
l
e
s
t
e
r
o
l
/
g
 
d
l
t
Diabetic
r=.82, p<.025Cardiovascular Diabetology 2004, 3 http://www.cardiab.com/content/3/1/6
Page 6 of 11
(page number not for citation purposes)
of apo B and apo E-containing lipoproteins in the arterial
wall. DS-containing PG in the arterial wall are produced
primarily by arterial smooth muscle cells and also by
endothelial cells [40,41]. Increased DS production by
these cells may result from increased activity of cytokines
[42] and growth factors [43] associated with the presence
of macrophages in the developing lesion. Enhanced syn-
thesis of CS/DSPG has been observed in cultured choles-
terol-enriched arterial smooth muscle cells [44]. In
addition, in vitro oxidized LDL was found to stimulate DS
and CS chain elongation of arterial smooth muscle cell PG
and specifically stimulate the expression and secretion of
biglycan [45]. Therefore our finding of a positive relation-
ship between DS and tissue cholesterol in both control
and diabetic arteries is consistent with an effect of lipids
on arterial DS synthesis.
By contrast HS was negatively associated with tissue cho-
lesterol in diabetic arteries only. HS is proposed to be anti-
atherogenic by several mechanisms. One is based on stud-
ies demonstrating anti-proliferative effects of HS on arte-
rial smooth muscle cells [25]. HSPG are produced by
arterial smooth muscle cells but the major contributors of
arterial HS are endothelial cells which secrete the
Identification of GAG by agarose electrophoresis Figure 2
Identification of GAG by agarose electrophoresis. Upper panel shows separation of GAG standards and representative samples 
on 0.5% agarose, at 150 volts, 2 hours in 0.05 M 1,3, diaminopropane, pH 9.0. GAG were stained with 0.1% toluidine blue, 0.1% 
alcian blue. Lower panel shows densitometric scans of stained GAG bands after electrophoretic separation. Lanes 1–3 con-
tained a mixture of equal amounts as shown of standard GAG. Lanes 4–6 show representative samples. HS, heparan sulfate; 
DS, dermatan sulfate; CS chondroitin sulfate.Cardiovascular Diabetology 2004, 3 http://www.cardiab.com/content/3/1/6
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basement membrane HSPG, perlecan, into the sub-
endothelial matrix (Figure 5 and [46]). We have recently
shown that in cultured human and bovine aortic endothe-
lial cells, high glucose exposure results in a structural
modification of perlecan that is consistent with the loss of
an HS GAG chain [46,47]. Studies have shown that sub-
endothelial HS inhibits monocyte binding to matrix pro-
teins such as fibronectin [23]. Thus the reduced arterial
HS associated with hyperglycemia may favor monoctye
retention in diabetic arteries.
HSPG have been shown to be hyperglycemia-sensitive tar-
gets in other tissues, most notably kidney. Several studies
of diabetic nephropathy have reported reduced HS in the
glomerular basement membrane of diabetic kidneys
[48,49]. Loss of HS was shown to be associated with
reduced charge permselectivity leading to increased uri-
nary albumin excretion [49]. Moreover, HS is a strong
inhibitor of mesangial cell growth and reduced HS in the
glomerular basement membrane is proposed result in
mesangial expansion and clinical nephropathy [49-51]. In
vitro, several lines of kidney cells have been used to dem-
onstrate that exposure to high glucose results in decreased
Plot of the association of tissue cholesterol and GAG distribution in segments of thoracic aorta from control (A) and diabetic  (B) monkeys Figure 3
Plot of the association of tissue cholesterol and GAG distribution in segments of thoracic aorta from control (A) and diabetic 
(B) monkeys. Percent GAG were measured as areas under the curves of stained GAG following agarose electrophoresis as 
shown in figure 2. Values used in the correlational analyses are the sum of GAG of guanidine extracted + non-guanidine 
extracted PG. Correlation coefficients and significance are shown. In A: percent DS, Y = 2.96X - 20.32. In B: percent DS, Y = 
3.90X - 28.51; percent HS, Y = -1.86X + 104.59. HS, heparan sulfate; DS, dermatan sulfate; CS, chondroitin sulfate; dlt, delipi-
dated tissue.
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production of HS GAG [52]. HS synthesis was decreased
in the retinas of diabetic rats thus providing a mechanism
for the reduction in retinal basement membrane anionic
sites and increased capillary permeability associated with
diabetes [53]. In a recent study, the HSPG, perlecan, was
reduced in the livers of diabetic mice [54]. This was pro-
posed to result in impaired remnant clearance from
plasma leading to the production of atherogenic lipopro-
teins. In vitro, high glucose was shown to reduce HS syn-
thesis in HepG2 cells thereby implicating hyperglycemia
with the decreased liver HSPG.
Conclusions
Although no group differences were detected in any of the
arterial GAG in these small groups of animals, our study
demonstrates that in the diabetic animals there was an
association between arterial content of HS and plasma
GHb. It suggests that diabetes-associated hyperglycemia
Plot of the association of plasma glycated hemoglobin and heparan sulfate content in segments of thoracic aorta from control  (A) and diabetic (B) monkeys Figure 4
Plot of the association of plasma glycated hemoglobin and heparan sulfate content in segments of thoracic aorta from control 
(A) and diabetic (B) monkeys. Glycated hemoglobin was measured in plasma isolated immediately prior to animal necropsy. HS 
was measured as percent of total GAG based on areas under the curves of stained GAG following agarose electrophoresis as 
shown in figure 2. HS mass was calculated from hexuronic acid values. Values used in the correlational analyses are the sum of 
GAG of guanidine extracted + non-guanidine extracted PG. Correlation coefficient and significance are shown. Y = -0.11X + 
2.05. HS, heparan sulfate; dlt, delipidated tissue; gHb, glycated hemoglobin.
Table 2: Group measurements of arterial GAG in control and diabetic monkeys
CS µg/mg dlt DS µg/mg dlt HS µg/mg dlt
C (7) 1.8 ± 0.3* 0.7 ± 0.2 0.9 ± 0.1
D (8) 2.1 ± 0.6 0.8 ± 0.3 1.1 ± 0.2
*Values are mean ± SEM of total CS, DS and HS in segments of thoracic aortas. C, control; D, diabetic; CS, chondroitin sulfate; DS, dermatan 
sulfate; HS heparan sulfate; dlt, delipidated tissue.
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may affect the synthesis or metabolism of HSPG by arte-
rial cells. This process is a potential target for intervention
in diabetes-related atherosclerosis and further studies are
needed to identify the biochemical mechanisms of glu-
cose-induced modification of arterial HS.
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Photomicrograph of section of thoracic aorta immunostained for HS GAG Figure 5
Photomicrograph of section of thoracic aorta immunostained for HS GAG. Paraffin sections prepared at necropsy were depar-
affinized, blocked and incubated with anti-HS GAG antibody (A) or no primary antibody (B). Cells were stained with 
hematoxylin.
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apolipoprotein B – apo B
glycosaminoglycans – GAG
guanidine HCL – GdnHCL
phospholipid – PL
triglyceride – TG
free cholesterol – FC
cholesteryl ester – CE
protein – Pro
thoracic aortas – TA
carotid artery – CA
hexuronic acid – UA
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